to work rapidly and cause relatively few side effects, while at the same time pointing out that the quality of the studies was generally poor and, importantly, there were no studies of longer term use.
Indeed, few robust studies were undertaken until Shelton et al 3 began a revival by using atypical antipsychotics as an adjunctive treatment strategy in patients with treatment resistant, nonpsychotic, unipolar depression. This idea drew on observations at the time that the atypical antipsychotics were effective in treating psychotic depression. 4 
| Treatment resistant depression (TRD)

| Defining and managing
Despite the many evidence based pharmacological treatments for depression, in real world practice many patients do not respond adequately to antidepressants and a significant proportion are unable to tolerate their side effects. 5 These nonresponders are often described as having "refractory" or "treatment resistant" depression (TRD) but the terms are variably defined and even definitions focusing on medication cannot achieve consensus as to what constitutes TRD. In most of the studies that are reviewed it may be more accurate to consider that the patient had an inadequate response rather than treatment resistance per se (see Table 1 for definitions of treatment resistance used).
Clinical studies in naturalistic settings consistently indicate that barely half of depressed patients respond to initial antidepressant monotherapy (the most common recommendation in practice guidelines) and that only one third eventually achieve satisfactory remission of symptoms (the desired goal in most guidelines). 6 Thus, in practice, alternative treatment strategies often have to be employed to achieve suitable outcomes in this large group of patients. These include assessing the adequacy of dose and treatment adherence; reviewing the diagnosis, including possible psychiatric and medical co-morbidity; and considering chronic social difficulties. The next steps are to increase the dose, switch to another antidepressant (possibly from a different class), combine antidepressants or add an adjunctive therapy. 7
| Adjunctive therapy
The words adjunctive and augmentation are often used interchangeably, but have different meanings. Augmentation implies that the added medication increases the efficacy of the primary medication, while adjunctive is simply the addition of a treatment that has effects independent of the primary medication. There are also synergistic agents, which work together with the primary medication to increase the efficacy of both. With some noted exceptions, most usage of atypical antipsychotics in depression appears to be adjunctive.
The main options for adjunctive treatment are lithium, atypical antipsychotics and, to a lesser degree, thyroxine. Lithium is perhaps the most versatile in that it can be added to any of the antidepressants currently in use and probably produces benefit both independently (as an antidepressant) and as an augmentation agent that facilitates the primary antidepressant effect. Its onset of action as an augmentation strategy is usually relatively prompt and if a response is not observed within 10-14 days then it is likely that it will be found to be ineffective. 8 In Canada, prescriptions for quetiapine per 100 Canadians rose from 3.2 in 2007 to 12 in 2012, and mood disorders were the most common diagnosis associated with quetiapine prescriptions. 12, 13 This raises a key question: is the large increase in prescribing atypical antipsychotics for depression justified by the quality of the available data? And, perhaps more importantly, do the benefits of treatment outweigh the risks? A Cochrane review that partly addressed these questions was published in 2010. 14 The present paper complements this review and provides a timely update. Specifically, it attempts to answer these questions by reviewing recent data concerning the reduction of depressive symptoms and considering the results in the context of the overall quality of life and general functioning of patients. keywords "adjunct*", "augment*", "antipsychotic", "depression" and excluding studies prior to 2009. To ensure inclusion of all available articles, reference lists of all relevant papers were also checked.
| ME THOD
Further, we identified and reviewed recently published guidelines which discuss the use of antipsychotics in MDD.
| RE SULTS
| Efficacy data -Quality
The Cochrane review noted a number of issues with the available data. First, as discussed earlier, there is no agreed definition of TRD, with different studies having used varying definitions ranging from nonresponse to one antidepressant to those who have failed more than four antidepressants. In reality, most studies use patients who have not responded to one or two antidepressants, which is probably better regarded as inadequate response.
Second, of the 28 RCTs reported in the Cochrane Database, 14 only
three gave information about the type of randomisation. Seven studies used identical capsules for blinding but no trials examined whether the blinding was effective. Given the significant adverse side effects of the tested drugs, the Cochrane authors felt that there was a high likelihood that patients and researchers would be unblinded. Third, the attrition rate in RCTs was moderate to high. In 10 studies, it was higher than 25%. Fourth, no study was judged to be free of selective reporting. Most trials had incomplete reporting of predefined outcomes and many only reported on adverse events if at least 5%-10% of participants had reported them. Finally, 21 of the studies were industry sponsored and four did not provide adequate information regarding funding. Hence, as noted by the Cochrane authors, "due to potential conflicts of interest a potential bias cannot be excluded." 14 Since the 2010 Cochrane Review, eight RCTs have compared adjunctive atypical antipsychotics to placebo (see Table 1 ). These recent studies were consistent with the Cochrane review, in that they showed a small but significant benefit from adjunctive atypical antipsychotics in most cases, and were subject to some of the same criticisms. The eight studies used different definitions of TRD, only three provided (partial) details of randomisation; six did not detail blinding procedures and none assessed the effectiveness of their blinding procedure; attrition rates were mixed (14%, 22.9%, 11%, 7.8%, 12.7%, 26.6%, 6.6% and 17.5%); and six studies failed to fully report side-effects. Seven of eight studies were funded by industry.
| Efficacy data -Outcome
The Cochrane review authors were cautious about efficacy, concluding that the evidence of positive treatment effects of olanzapine and risperidone augmentation has to be considered as rather low, and that tolerability was worse in terms of weight gain and sedation (olanzapine) and prolactin (risperidone). Somewhat more data suggest a benefit of quetiapine and aripiprazole augmentation in some aspect of efficacy, but this again must be weighed against worse overall tolerability, such as more sedation (quetiapine) and more weight gain (quetiapine, aripiprazole) compared to single-treatment regimens with antidepressants. Returning to the depression severity scores, it is important to consider what these differences in depression severity scores actually measure. Spielmans et al 24 reported that change on the MADRS score was the most commonly reported outcome. The MADRS consists of 10 items each rated on a 0-6 scale giving a potential total of 60 points. The pooled difference for placebo vs adjunctive antipsychotics in mean change in MADRS score was 2.69 points in the Spielmans et al 24 meta-analysis. Because of the sedating effects of most atypical antipsychotics, they speculated that it was possible the effect may be confined to a few symptoms rather than the overall depression score on the MADRS. While it is rare for trials to publish individual MADRS item scores, the pooled analysis of two quetiapine RCTs did so. 29 From their figures, it appears that the most prominent effect of quetiapine at 300 mg and 150 mg was on the MADRS item "reduced sleep," both at 1 week and 6 weeks. The effects on sadness, inner tension, pessimistic thoughts and suicidal thoughts were less marked and effects on other MADRS items were not significant. In contrast, the pooled figures for adjunctive brexpiprazole reported that the medication had most effects on sadness, inner tension, lassitude, inability to feel and pessimistic thoughts and no influence on sleep. 30 On other outcome measures such as quality of life or functioning, atypical antipsychotic adjunctive therapy has been shown to have minimal or no benefits. Spielmans et al 24 report that olanzapine and quetiapine had no benefits on quality of life, while the effects of aripiprazole were significant but small. Risperidone appeared most useful in improving quality of life measures but, as they pointed out, risperidone had the smallest sample size and the largest risperidone trial published did not report on quality of life at the primary endpoint but 2 weeks later.
| Adverse effects
| Short term
All studies in the Cochrane review reported significantly increased adverse events using atypical antipsychotics. These were akathisia (aripiprazole), sedation (quetiapine, OFC and aripiprazole), abnormal metabolic laboratory results (quetiapine and OFC) and weight gain (all four drugs, particularly OFC). While most trials used a structured instrument to collect data on adverse events, many limited the items to EPS and akathisia, weight and sometimes sexual functioning. The more recent studies listed in Table 1 appear to have more carefully collected data on adverse events. Those that were more common were weight gain (aripiprazole, ziprasidone, brexpiprazole), akathisia and tremor (aripiprazole, quetiapine, cariprazine, brexpiprazole) and insomnia (cariprazine). However, the akathisia was predominantly mild and weight gain over a 6-8 week period was usually less than 1 kg.
| Long term
To date, there are no data on the long-term adverse events associated with adjunctive atypical antipsychotics in double-blind studies of major depression. The longest study is an industry study on the efficacy and safety of OFC for up to 47 weeks. 31 Clinically significant weight gain (defined as ≥7% increase in weight) was observed in 55.7% of the patients who remained on OFC throughout the study.
In addition, adverse changes in glucose, triglyceride and cholesterol were greater in OFC treated patients and more OFC treated patients experienced high prolactin values. There was no change in ECGs and no difference in induction of mania.
There are multiple studies reporting metabolic changes, including dyslipidaemia, diabetes, prolactin increase, thyroid disorders, obesity, cardiovascular, respiratory and renal diseases, as well as movement and seizure disorders in patients taking atypical antipsychotics for other conditions such as schizophrenia. 32, 33 These findings are of significant concern as data from the US National Health and Nutrition Examination Surveys 34 has reported that both moderate to severe depressive symptoms and antidepressant use are independently associated with increased obesity and metabolic changes. Therefore, the adjunctive use of atypical antipsychotics for long periods of time needs to be administered with caution.
| What do treatment guidelines tell us?
We identified and reviewed a number of guidelines which discuss the use of adjunctive antipsychotics in major depression. The
American Psychiatric Association (APA) most recent 3rd Edition
Practice Guidelines was published in 2010. 35 Mood Disorder Guidelines, published in 2015, was similarly cautious. 40 While noting that placebo controlled studies have found that aripiprazole, olanzapine, quetiapine and risperidone can be effective as adjunctive treatments, they also noted that, excepting quetiapine, they are "off-label"-meaning that they are not formally indicated for adjunctive treatment in Australia or New Zealand.
Their advice was that adjunctive antipsychotic treatment may be used in TRD but that, once a stable response has been achieved, the gradual withdrawing of the agent should be considered since there is no evidence of long-term efficacy. The Guidelines also recommended that adverse effects be closely monitored since they are of great concern, especially in the context of long-term therapy. In summary, all the guidelines acknowledge that there is an evidence base to support adjunctive treatment with antipsychotics in patients with major depression, but all guidelines caution about the potential side effects and most do not comment on how long these agents should be used.
| RECOMMENDATIONS
| Where does this leave us?
This review highlights the potential concerns regarding the use of atypical antipsychotics as an adjunctive treatment in people with major depression. The first concern is who is being treated? While treatment resistant depression is considered the clinical indication for adjunctive treatment in the majority of studies reviewed, the patients more accurately may be described as having an inadequate response rather than being treatment resistant. This is a potential problem for two reasons. It does not test the medication in the population where clinicians may wish to use adjunctive antipsychotics, and it may reduce the perceived efficacy of the drugs, since a significant proportion of those with inadequate response rather than "true" treatment resistance will go on to recover regardless of specific treatments.
The second concern is the quality of the efficacy data. Most studies were industry sponsored. None assessed whether the blinding was effective despite the prominent side effects of the study medication, and few were judged to be free of selective reporting, with adverse events, for instance, not always reported clearly.
The third concern is that, despite these inadequacies, the effect sizes of adjunctive antipsychotics in reducing depressive symptoms were small.
Fourth is the significant side effect burden of atypical antipsychotics reported in all studies and a lack of data on the long-term adverse effects associated with adjunctive antipsychotic use in major depression.
Finally, we are concerned that there are few trials comparing atypical antipsychotics with other strategies in patients with an inadequate response to antidepressants. A recent, large, well-conducted trial attempted to answer these concerns. 41 Over 1500 patients who were unresponsive to at least one antidepressant 
| Clinical recommendations
The Clinical accounts report that the principal benefit of using antipsychotics is found in patients with extensive ruminations, which are almost delusional in intensity, as well as those with marked psychomotor changes, major sleep problems, and guilt and remorse, rather than simply those who have failed to respond to one or two antidepressants. In such cases, the short-term use of adjunctive antipsychotics may be justified. We would also argue that these are the type of patients that need to be included in future clinical trials in order to obtain a better idea of the cost-effectiveness of adjunctive antipsychotics.
In summary, adjunctive antipsychotics may be useful in selected patients with major depression who are treatment resistant. One advantage of adding an antipsychotic is that its clinical effect is usually apparent within the first week and the medication can then be tapered and stopped after a relatively brief treatment trial. The current evidence only supports relatively short-term use of these treatments, which then only need to be maintained for a further short period of time if they are felt to be of benefit. This positions the use of adjunctive antipsychotics as "facilitators" of an acute response to treatment, and it is important to note that their effect is likely to be most helpful in patients with severe and disabling depression. 
| Research recommendations
| CON CLUS ION
There is a moderately large database suggesting that adjunctive antipsychotics may be useful in treating TRD. However, the effect size is small, there are issues with the quality of the efficacy data, the side effects are moderate to severe, and the varying defi- 
